Quick Take
BioVie (OTCQB:BIVI) has filed to raise $15 million in a U.S. IPO, according to an amended registration statement.
The company is developing a terlipressin-based therapy for the treatment of ascites.
BIVI is a tiny biopharma with little in the way of resources and a long road ahead for treatment approval, so the IPO is ultra-high risk.
Company & Market
Los Angeles, California-based BioVie was founded in 2013 to develop and market new therapies for the treatment of life-threatening chronic liver diseases and associated complications.
Management is headed by Chairman and